<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223521</url>
  </required_header>
  <id_info>
    <org_study_id>TYH2010224</org_study_id>
    <nct_id>NCT01223521</nct_id>
  </id_info>
  <brief_title>Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion.</brief_title>
  <official_title>Systematic Provision of Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion. A Randomized, Prospective Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized prospective study on the effects of immediate provision of intrauterine
      contraception after first trimester induced abortion - effects on repeat abortions and
      quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of repeat abortions</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expulsions</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Immediate intrauterine contraception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immediate intrauterine contraception</intervention_name>
    <description>A Cu-IUD or LNG-IUS is inserted after abortion.</description>
    <arm_group_label>Immediate intrauterine contraception</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duration of pregnancy &lt; 12 weeks.

          -  Age â‰¥18 years

        Exclusion Criteria:

          -  Contraindication for spiral insertion: uterine anomaly, infection, copper allergy
             (Cu-IUD).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oskari Heikinheimo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satu P Suhonen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>City of Helsinki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Obstetrics and Gynecology, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>October 18, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Elina Kuronen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Abortion</keyword>
  <keyword>First trimester</keyword>
  <keyword>Intrauterine device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
